8:50 am Chair’s Opening Remarks

9:00 am The Importance of Different Vaccine Platforms, Neoepitope Selection & Clinical Trial design to Show Vaccine-induced Clinical Efficacy


  • Exploring the contribution of TMB, heterogeneity and neoepitope quality parameters for successful outcomes
  • Which patient populations could benefit from a neoantigen vaccine?
  • What is the ideal combination strategy for neoantigen vaccines?

9:30 am The Impact of Stimulatory and Inhibitory Neoantigens Selected with the ATLAS Bioassay: Clinical and Pre- Clinical Results

  • Hubert Lam Director, Pre-clinical Development, Genocea


  • ATLAS identifies stimulatory and inhibitory CD4+ and CD8+ T cell responses to neoantigens and common antigens
  • Preclinical models show the deleterious impact of inhibitory T cell responses on anti-tumor immunity
  • Be careful, common neoantigens may differ from common mutations
  • The GEN-009 immunotherapy, designed with personalized ATLAS-identified stimulatory neoantigens has resulted in unprecedented breadth of immune response in the ongoing GEN-009 101 Phase 1/2a clinical trial

10:00 am What Does Brexit Mean for Production of Neoantigen Therapies?


  • Different national agencies have different attitudes
  • Make early contact with the regulator

10:30 am Morning Refreshments & Networking


11.30 High-affinity Neoepitope-Specific T cells Accumulate in Tumours

• NeoAg-specific CD8 T cells cover broad ranges of avidities (structural and functional)

• Unlike the functional avidity, the structural avidity of neoAg-specific CD8 T cells is higher than that of TAA-specific CD8 T cells

• CD8 T cells bearing high avidity TCR better upregulate tumor-homing receptors, infiltrate tumour and control tumours

Alexandre Harari, Group leader, Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne


12.00 Personalized Cancer Vaccines: Enhancing Neo-epitope Presentation

• Update on current personalized cancer vaccine clinical approach, successes and challenges

• Basic research approaches to enhance presentation of neo-epitopes via various cellular perturbations

• Show casing some high throughput targeted spectrometric tools for further characterizing epitopes for binding affinity various HLA allele and presentation

Jennie Lill, Senior Director of Proteomics & NGS, Genentech


12.30 Are Immunogenic Tumours the Best Targets of Tumour Vaccination?

  • Identifying the best targets for tumour vaccination
  • Tumour infiltration and PDL1expression to identify the tumours that are more sensitive to vaccines
  • Assessing non immunogenic tumours
  • Outlining considerations for the future of neoantigens

Kostas Kosmatopoulos, CEO, Vaxon Biotech



1:00 pm TG4050 : Viral immunotherapy meets AI technology


  • TG4050 is based on a decade long expertise in designing viral vectors
  • Viral immunotherapy constitutes a promising modality harnessing the natural sensitivity of immune system to virus to target cancer cells
  • Viruses can be modified to alter their immunogenic properties and enhance anti-tumor activity
  • A review of how different viruses can be combined to enhance immunogenicity and optimize lead time

13:30 pm Lunch

2:30 pm Nouscom Viral Vectored Vaccines Encoding Many Neoantigens Synergize With Immunotherapies Reverting Tumour Immune Suppression


  • Nouscom Cancer vaccines targeting neoantigens:
  • Rely on effective neoantigens prediction methods
  • Can encode a large number of neoantigens
  • Induce a robust neoantigens’ specific CD4 and CD8 T cell immunity
  • Cure large established tumours in mice when combined with checkpoint blockade

3:00 pm Panel Discussion: Evaluating Combination Therapies


  • The hasty evolvement of combination strategies
  • Combinational therapies employing both neoantigen-based approaches and immune checkpoint blockade (ICB) are underway to overcome ICB-induced immune resistance and maximize antitumor immune activity
  • Investigating the safety and efficacy of neoantigen vaccine therapy plus chemotherapy in adjuvant setting
  • Discuss regulatory pathway and limitations to approve two new drugs
  • How to identify a clear biologic effect caused by combination
  • Improving Clinical Efficacy through Immunotherapy Combinations

3:30 pm Extrapolation of epitope prediction from IO onto infectious diseases (lessons learned)


  • Differences and synergies between personalized/shared neoantigen identification, and target prediction for infectious diseases
  • Exploration of different IO epitope prediction tools and their extrapolation capabilities for general infectious diseases
  • Use case: designing an optimal construct for intranasal RNA-based SARS-CoV2 vaccine

4:00 pm Chairs Closing Remarks

4:15 pm End of Day 2 & Close of Neoantigen Summit